The up-dosing phase is marked by increased IL-10+B-cells with allergen-specific PD-L1 up-regulation, while effector Th1/Th17 cells and CCR6+IL-17+FoxP3+T-cells decrease. The conversion phase exhibits Th17 recovery in the absence of Th2cells. The tolerance-mounting phase after three years of treatmen...
ORGANISM(S): Homo sapiens